Jacob Kagan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Mitochondria as a target for early detection and diagnosis of cancer
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland 20852, USA
    Crit Rev Clin Lab Sci 42:453-72. 2005
  2. ncbi Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:4545-9. 2007
  3. ncbi Proteomic analysis of cancer-cell mitochondria
    Mukesh Verma
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 3:789-95. 2003
  4. ncbi [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study
    Lori J Sokoll
    Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 180:539-43; discussion 543. 2008
  5. ncbi Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio
    Howard L Parnes
    Prostate and Urologic Cancer Researh Group, Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
    J Urol 171:S68-74; discussion S75. 2004
  6. ncbi The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology
    William E Grizzle
    University of Alabama at Birmingham, Birmingham, AL, USA
    Urol Oncol 22:337-43. 2004
  7. ncbi Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility
    O John Semmes
    Department of Microbiology and Molecular Cell Biology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Clin Chem 51:102-12. 2005
  8. ncbi Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:44-52. 2008
  9. ncbi SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:53-60. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Mitochondria as a target for early detection and diagnosis of cancer
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland 20852, USA
    Crit Rev Clin Lab Sci 42:453-72. 2005
    ....
  2. ncbi Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:4545-9. 2007
    ....
  3. ncbi Proteomic analysis of cancer-cell mitochondria
    Mukesh Verma
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 3:789-95. 2003
    ....
  4. ncbi [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study
    Lori J Sokoll
    Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 180:539-43; discussion 543. 2008
    ..This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy...
  5. ncbi Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio
    Howard L Parnes
    Prostate and Urologic Cancer Researh Group, Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
    J Urol 171:S68-74; discussion S75. 2004
    ..Two large phase 3 trials, the Prostate Cancer Prevention Trial and the Selenium and Vitamin E Cancer Prevention Trial, which are ongoing, are also sponsored by the National Cancer Institute...
  6. ncbi The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology
    William E Grizzle
    University of Alabama at Birmingham, Birmingham, AL, USA
    Urol Oncol 22:337-43. 2004
    ..The methodologies used for this evaluation will prove useful for guiding future biomarker studies in this challenging disease...
  7. ncbi Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility
    O John Semmes
    Department of Microbiology and Molecular Cell Biology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Clin Chem 51:102-12. 2005
    ..This report describes the first stage of a National Cancer Institute/Early Detection Research Network-sponsored multiinstitutional evaluation and validation of this approach for detection of prostate cancer...
  8. ncbi Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:44-52. 2008
    ..Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1...
  9. ncbi SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:53-60. 2008
    ..This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma...